Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
Conditions
Interventions
Nivolumab
Ipilimumab
+2 more
Locations
71
United States
Local Institution - 0080
Tucson, Arizona, United States
Local Institution - 0051
Fountain Valley, California, United States
Local Institution - 0070
Fort Myers, Florida, United States
Local Institution - 0073
Gainesville, Florida, United States
Local Institution - 0036
Orange City, Florida, United States
Local Institution - 0045
Pensacola, Florida, United States
Start Date
October 3, 2022
Primary Completion Date
December 27, 2022
Completion Date
December 27, 2022
Last Updated
February 28, 2024
NCT07431827
NCT06427941
NCT07164313
NCT07361497
NCT07510724
NCT06745882
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions